Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R Millican-Slater
PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?
Breast Cancer Research
Cancer Research
Oncology
Related publications
Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma
Clinical Breast Cancer
Cancer Research
Oncology
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab
Oncologist
Cancer Research
Medicine
Oncology
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers Treated With Neoadjuvant Chemotherapy
Targeted Oncology
Cancer Research
Oncology
Pharmacology
Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer
Journal of Cancer Research and Clinical Oncology
Medicine
Cancer Research
Oncology
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab
Cardio-Oncology
Treatment Results in Patients With Ductal Carcinoma in Situ Treated With Adjuvant Radiotherapy
Turkish Journal of Medical Sciences
Medicine
Biologic and Immunologic Effects of Preoperative Trastuzumab for Ductal Carcinoma in Situ of the Breast
Cancer
Cancer Research
Oncology
